TAILORx: Prospective phase 3 trial validating a 21-gene expression assay in breast cancer | Dr Clifford Hudis at ECC 2015 - 101271

Spotlight
Video

TAILORx: Prospective phase 3 trial validating a 21-gene expression assay in breast cancer | Dr Clifford Hudis at ECC 2015

EMJ has 458 videos Subscribe Here

Loading........
Description: At the European Cancer Congress (ECC) 2015, Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, New York, NY, discusses the low-risk registry results from Trial Assigning IndividuaLized Options for Treatment (TAILORx), which is a prospective phase 3 clinical trial designed to evaluate the role of endocrine therapy and chemoendocrine therapy in patients with oestrogen receptor (ER)-positive, HER2-negative, axillary node-negative breast cancer whose treatment was guided by the 21-gene expression assay results, the Oncotype DX® Breast Cancer Assay Recurrence Score® results.

–––

European Medical Journal

Website: http://emjreviews.com/...
Twitter: https://twitter.com/EMJRevi...
Facebook: https://www.facebook.com/em...
Shared By : EMJ
Posted on : 10/01/15
Added : 2 years ago
Category : Breast Cancer



Recommended

Nothing found.

More From EMJ

Nothing found.